MENLO PARK, Calif., Sept. 11, 2016 (GLOBE NEWSWIRE) --
Geron Corporation (Nasdaq:GERN) will host a conference call on September 12, 2016, at 8:00 a.m. Eastern Time to provide an update on the imetelstat Phase 2 trial in myelofibrosis and Phase 2/3 trial in myelodysplastic syndromes.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 80522983. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast will also be available through the company’s website at http://www.geron.com under Events. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through October 13, 2016.
===================
It was announced only one day in advance. What could this be? Change in dosing?
Geron conference call 12 Sept, 2016, 08:00 a.m. Eastern Time
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
Fishermangents
- Site Admin
- Posts: 529
- Joined: Thu Dec 03, 2015 3:39 pm
-
irishtrader52
- Posts: 44
- Joined: Tue Dec 15, 2015 2:53 am
Re: Geron conference call 12 Sept, 2016, 08:00 a.m. Eastern Time
Hi Fish - I think this must come as a surprise especially announced on a Sunday morning for next day. Hopefully, some good 'new' news. John is great more than 4 years after diagnosis of high risk MF. I don't think John is the only one - especially given on-going expansion of distribution - I mean study - sites. Good luck to all!
-
Fishermangents
- Site Admin
- Posts: 529
- Joined: Thu Dec 03, 2015 3:39 pm
Re: Geron conference call 12 Sept, 2016, 08:00 a.m. Eastern Time
Some comments from SA:
Leviek:
"Scarlet has repeatedly stated that no announcements would be made regarding the interim results, which are highly likely to be known at this time. It is September, and they have repeatedly said the interim results will be known by the end of the third quarter, about 19 days from now. THEY KNOW!
Another very important consideration is the timing of this conference. As 27717033 alluded, it is generally SOP in the business to dump bad news on Friday, after the close. It is positive, logically, to present good news just before the opening on Monday. For example, Abiomed has made it a habit to present their recent earning's news before market openings, and every single report in the last couple of years has been much better than street expectations.
Also, this is a conference call, not a written update. They may be trying to get maximum attention to this. Why would they publicize this in such a way? Does anyone really think they give a "stow high" about publicizing bad news? They would simply send a news release, not have an early morning Monday conference, where every single investor in Geron, all analysts, etc. would be there to not only hear the news but I believe to ask questions?
If it is just about dosing schedules (remember that John is now on 7.4) and a move to phase III in MDS, it would be positive across the board because that would signify positive results and steady-as-she-goes progress. Analyst's would raise their targets on this."
Hoosier:
"At this point, I'd guess the interim reviews are complete to the point they've decided to make some changes to the trials. The most likely being a revision (or elimination) of the 4.7mg/kg dosage within the IMbark trial. Given their sensitivity over timely & accurate sharing of material information (result of recent lawsuits), they'd be wise to error on the side of communicating ANY changes to the trials (my opinion).
The IMbark (MF) enrollment rate could use a boost. Thus, assuming they're seeing some responses, a high-level public acknowledgement of those responses could be a strategic attempt to boost the enrollment rate for the remainder of the trial.
The MDS trial starts at 7.5 mg/kg and includes provisions to increase the dose should the patient be able to tolerate it. That seems a very good approach to me. Thus, I'd guess most likely MDS revision would be the transition to the Phase 3 portion of the trial."
MTB:
"Its looking more and more like that unexpected price rise last week was leaked info. If the market didn't crater GERN may have been in the 3.20's Friday. I think its good news, we'll see very soon."
Analyst X (alias Greg-E):
"MTB- in addition to the market action, there are other tea leaves we've been discussing- Hoosier's great find posted on this thread about JNJ recruiting for a Director, New Product Development-Hematology with MF/MDS/AML experience, the information ibmiked posted about the apparently good prospects for settling the two year old shareholder litigation, the comments from JNJ's Caruso posted by CKTC about JNJ being as excited as ever about the drugs in the pipeline that they touted on May 20th 2015 as being near term blockbusters one of which was Imetelstat- all these could easily be correlated with positive underlying news. But the unpredictable and sudden nature of the announcement combined with the long history of Geron leave plenty of room for worry too. Like the Allied staff in England on the evening of June 5th 1944, we'll know for better or for worse soon!"
Leviek:
"Scarlet has repeatedly stated that no announcements would be made regarding the interim results, which are highly likely to be known at this time. It is September, and they have repeatedly said the interim results will be known by the end of the third quarter, about 19 days from now. THEY KNOW!
Another very important consideration is the timing of this conference. As 27717033 alluded, it is generally SOP in the business to dump bad news on Friday, after the close. It is positive, logically, to present good news just before the opening on Monday. For example, Abiomed has made it a habit to present their recent earning's news before market openings, and every single report in the last couple of years has been much better than street expectations.
Also, this is a conference call, not a written update. They may be trying to get maximum attention to this. Why would they publicize this in such a way? Does anyone really think they give a "stow high" about publicizing bad news? They would simply send a news release, not have an early morning Monday conference, where every single investor in Geron, all analysts, etc. would be there to not only hear the news but I believe to ask questions?
If it is just about dosing schedules (remember that John is now on 7.4) and a move to phase III in MDS, it would be positive across the board because that would signify positive results and steady-as-she-goes progress. Analyst's would raise their targets on this."
Hoosier:
"At this point, I'd guess the interim reviews are complete to the point they've decided to make some changes to the trials. The most likely being a revision (or elimination) of the 4.7mg/kg dosage within the IMbark trial. Given their sensitivity over timely & accurate sharing of material information (result of recent lawsuits), they'd be wise to error on the side of communicating ANY changes to the trials (my opinion).
The IMbark (MF) enrollment rate could use a boost. Thus, assuming they're seeing some responses, a high-level public acknowledgement of those responses could be a strategic attempt to boost the enrollment rate for the remainder of the trial.
The MDS trial starts at 7.5 mg/kg and includes provisions to increase the dose should the patient be able to tolerate it. That seems a very good approach to me. Thus, I'd guess most likely MDS revision would be the transition to the Phase 3 portion of the trial."
MTB:
"Its looking more and more like that unexpected price rise last week was leaked info. If the market didn't crater GERN may have been in the 3.20's Friday. I think its good news, we'll see very soon."
Analyst X (alias Greg-E):
"MTB- in addition to the market action, there are other tea leaves we've been discussing- Hoosier's great find posted on this thread about JNJ recruiting for a Director, New Product Development-Hematology with MF/MDS/AML experience, the information ibmiked posted about the apparently good prospects for settling the two year old shareholder litigation, the comments from JNJ's Caruso posted by CKTC about JNJ being as excited as ever about the drugs in the pipeline that they touted on May 20th 2015 as being near term blockbusters one of which was Imetelstat- all these could easily be correlated with positive underlying news. But the unpredictable and sudden nature of the announcement combined with the long history of Geron leave plenty of room for worry too. Like the Allied staff in England on the evening of June 5th 1944, we'll know for better or for worse soon!"